Bayberry Allergy Shots: Coastal Southeast SCIT Guide (Myricaceae)
Bayberry (Morella cerifera, family Myricaceae — not Myrtaceae) is the underdocumented major aeroallergen of the coastal Southeast, with the Jacinto 1992 JACI provocation study showing 15% SPT positivity, 92% positive nasal challenges, and 57% positive bronchial challenges in sensitized subjects. Despite having no IUIS-named allergen and no SCIT RCT, bayberry has more clinical provocation evidence than many formally characterized tree species.
Bayberry (Southern Wax Myrtle) Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to bayberry (southern wax myrtle) — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of bayberry (southern wax myrtle) allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of bayberry (southern wax myrtle) immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of bayberry (southern wax myrtle) extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for bayberry (southern wax myrtle) allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing bayberry (southern wax myrtle) extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription bayberry (southern wax myrtle) immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat bayberry (southern wax myrtle) allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Bayberry (Southern Wax Myrtle)?
The biology, taxonomy, and clinical fingerprint of Bayberry (Southern Wax Myrtle) — the foundation of how SCIT targets it.
Bayberry / southern wax myrtle (Morella cerifera, family Myricaceae) releasing wind-borne pollen from catkins in the coastal Southeast, February–April. The aromatic waxy berries are post-pollination structures and do not drive IgE allergy.
- Scientific name
- Morella cerifera (syn. Myrica cerifera)
- Family
- MyricaceaeBayberry family — NOT Myrtaceae (a common botanical error in older sources)
- Type
- Evergreen shrub/small tree pollen (wind-pollinated)
- Native to
- Atlantic and Gulf coastal plain, from New Jersey south to Florida and west to Texas
- Allergen proteins
- No IUIS-named Morella or Myrica allergen as of May 2026 — molecular allergen catalogue is empty
- Particle size
- N/A — pollen size not formally characterized in IgE literature
- Avoidance difficulty
- Very difficult
How Bayberry (Southern Wax Myrtle) Allergy Presents
Symptoms by body system — useful for distinguishing Bayberry (Southern Wax Myrtle) sensitivity from overlapping allergies and infections.
Respiratory
- Sneezing and nasal congestion during February–April pollen release in the coastal SE
- Clear rhinorrhea confirmed as allergen-specific in 92% of nasal challenges per Jacinto 1992
- Asthma exacerbation — 57% of sensitized asthmatics showed positive bronchial challenges in Jacinto 1992
- Symptoms overlap with co-occurring live oak, pecan, and bayberry season making differential diagnosis important
- Earlier season onset than most spring tree pollens — February in Florida and coastal Georgia
Ocular
- Itchy, watery eyes during the February–April coastal pollen season
- Allergic conjunctivitis concurrent with nasal symptoms in sensitized individuals
- Periorbital swelling in patients with high IgE burden to bayberry
Dermal
- No documented OAS food cross-reactivity for Morella cerifera pollen allergens
- Contact dermatitis from bayberry wax or leaf preparations is rarely reported
- The aromatic berries used in candles are post-pollination structures and do not drive pollen IgE allergy
Systemic
- Fatigue from chronic allergic rhinitis during the extended coastal SE spring season
- Sleep disruption from nasal congestion in residents of coastal Georgia, Carolinas, and Florida
- Asthma exacerbations — the 57% positive bronchial challenge rate (Jacinto 1992) supports systemic impact in asthmatics
- Headache from chronic sinus inflammation during February–April
Southern bayberry deserves more clinical attention than it gets — Jacinto's 1992 bronchial challenge data show 57% asthma provocation positivity in sensitized patients, comparable to many IUIS-characterized species, yet the IUIS allergen catalogue still lists nothing for Morella cerifera. That is an evidence gap, not a reason to dismiss the allergen.
When & Where Bayberry (Southern Wax Myrtle) Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: March across the coastal Southeast; February in Florida and coastal Georgia· ~6–8 weeks from February through April along the Atlantic and Gulf coastal plain
US Exposure Map
8 high-intensity statesWhat Bayberry (Southern Wax Myrtle) Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Bayberry cross-reactivity is incompletely characterized — possible Betulaceae (Fagales) cross-reactivity has been suggested but not formally quantified; no OAS food list exists for Morella cerifera sensitization.
Possible Betulaceae cross-reactivity suggested but not formally quantified; shared Myricales-Fagales evolutionary proximity
Is SCIT Right for Your Bayberry (Southern Wax Myrtle) Allergy?
Answer five questions to assess whether bayberry allergy shots may be appropriate for your coastal Southeast spring allergy profile.
How severe are your February–April coastal SE allergy symptoms?
The Bayberry (Southern Wax Myrtle) SCIT Protocol
Bayberry SCIT uses non-standardized aqueous Morella cerifera extract, typically included in a southeastern X-tree prescription mix alongside live oak, pecan, and other regionally confirmed aeroallergens. Curex IgE testing differentiates bayberry sensitization from co-occurring SE aeroallergens like live oak, bald cypress, and bahiagrass that share the February–April symptom window — a critical step before designing a regional SCIT mix.
Starting from the most diluted vial (1:10,000 w/v), the bayberry extract concentration is incrementally increased at each step. With Curex, the prescribing physician supervises the first dose and every dose change live over Zoom and confirms a prescribed epinephrine auto-injector on hand. Initiating build-up in fall allows reaching maintenance before the February–April coastal SE pollen season.
Monthly maintenance injections sustain the immunologic tolerance developed during the build-up phase. The Jacinto 1992 provocation data provide the clinical justification for bayberry inclusion, though no maintenance-efficacy RCT exists specifically for this species.
After a complete SCIT course, lasting benefit extending 7–12 additional years is expected based on the broader tree-pollen SCIT literature. The decision to discontinue is individualized, particularly for patients with comorbid asthma where the 57% positive bronchial challenge rate (Jacinto 1992) indicates high respiratory risk from untreated sensitization.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Bayberry (Southern Wax Myrtle) SCIT
Bayberry has no species-specific SCIT RCT, but Jacinto et al. (JACI 1992) provides the strongest provocation evidence of any non-IUIS-characterized tree allergen in the southeastern US — 92% positive nasal challenges and 57% positive bronchial challenges in sensitized subjects.
- Positive nasal challenge in sensitized SE rhinitis subjects92%Jacinto CM, Nelson RP Jr, Bucholtz GA et al. JACI 1992;90:312 — N=13 sensitized rhinitis subjects
- Positive bronchial challenge in sensitized SE asthmatic subjects57%Jacinto CM, Nelson RP Jr, Bucholtz GA et al. JACI 1992;90:312 — sensitized asthmatic subjects
- SPT positivity to bayberry in a 400-patient SE allergic cohort15%Jacinto CM, Nelson RP Jr, Bucholtz GA et al. JACI 1992;90:312 — 60/400 patients
Bayberry has the strongest provocation evidence of any non-IUIS-characterized tree allergen in the southeastern US — the Jacinto 1992 nasal and bronchial challenge data are the gold standard of clinical evidence short of an RCT. No species-specific SCIT efficacy trial exists, so clinical practice extrapolates from the AAAAI Practice Parameter framework (Cox et al., JACI 2011) and regional empirical data. Patients should understand that bayberry SCIT response is likely but not RCT-proven.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Bayberry (Southern Wax Myrtle) SCIT Side Effects
Bayberry SCIT follows the standard inhalant immunotherapy safety profile; no bayberry-specific adverse reaction signal has been reported beyond the class-level SCIT literature.
Local reactions
4 documentedSystemic reactions
4 documentedBayberry-sensitized asthmatics warrant extra vigilance given the documented 57% bronchial challenge positivity rate in this population (Jacinto 1992). With Curex at-home SCIT, the prescribing physician supervises the first dose and every dose change live over Zoom, confirms a prescribed epinephrine auto-injector on hand before the first injection, and checks asthma control (spirometry) before each dose.
SCIT vs Alternatives for Bayberry (Southern Wax Myrtle)
For bayberry-allergic patients in the coastal Southeast, SCIT is the only disease-modifying option; pharmacotherapy provides symptom relief but no lasting benefit after stopping treatment.
| Criterion | At-Home SCIT (Curex)Best | SLIT Drops | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Moderate (provocation-validated) | Limited (extrapolated) | Minimal (ubiquitous coastal shrub) | Good symptom control |
| 5-yr cost | $3,500–$15,000 | $1,500–$4,000 | $0–$300/yr | $200–$1,200/yr |
| Duration | 3–5 years | 3–5 years | Indefinite | Indefinite |
| Convenience | At-home self-injection; weekly then monthly | Daily at home | Lifestyle adjustments | Daily pills/sprays |
| Safety | Zoom-supervised dosing + prescribed epi | Self-administered | No medical risk | Generally safe |
| Lasting effect | 7–12 yrs post-course | Ongoing use needed | No lasting change | No lasting change |
At-Home SCIT (Curex)Best
SLIT Drops
Avoidance
Medications
For coastal SE patients with confirmed bayberry sensitization and inadequate pharmacotherapy response, SCIT incorporating bayberry alongside regional co-allergens is the evidence-based next step. Curex IgE testing distinguishes bayberry from the co-occurring aeroallergens, and Curex now delivers that SCIT as an at-home allergy shot at $129/month: a bayberry-inclusive serum compounded under USP <797>, with the first dose and every dose change supervised live over Zoom, a prescribed epinephrine auto-injector confirmed on hand, and allergist-overseen escalation — for patients who prefer at-home therapy.
What Bayberry (Southern Wax Myrtle) SCIT Actually Costs
Bayberry SCIT is billed under standard immunotherapy CPT codes (95115, 95117, 95165) as part of a southeastern X-tree mix. Most major insurers cover it when prescribed by a board-certified allergist with documented sensitization. Prior authorization requirements vary; some payers require documented pharmacotherapy failure before approving immunotherapy for non-standardized tree extracts.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your bayberry (southern wax myrtle) allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Bayberry (Southern Wax Myrtle) SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Bayberry (Morella cerifera, also called southern wax myrtle) is an evergreen shrub or small tree native to the Atlantic and Gulf coastal plain from New Jersey to Florida and west to Texas. Unlike most ornamental plants, bayberry is wind-pollinated — its pollen is released from catkins and carried through the air, allowing it to reach nasal passages and trigger IgE-mediated allergic rhinitis and asthma in sensitized individuals. The Jacinto et al. (JACI 1992) study confirmed this mechanism directly: 15% of 400 southeastern allergic patients tested positive on skin prick test, and 92% of sensitized rhinitis subjects produced positive nasal challenge responses when exposed to the extract. Bayberry is also widely planted as a residential landscape shrub in coastal communities, extending exposure beyond wildland settings.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.